首頁 › 慢性淋巴性白血病 › 印第安納 › Fort Wayne
Fort Wayne, IN 的 慢性淋巴性白血病 臨床試驗
7 項針對 慢性淋巴性白血病 的研究正在 Fort Wayne（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
招募中3 期
- Fort Wayne Medical Oncology and Hematology ( Site 5444), Fort Wayne
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
招募中3 期
- Study Site 101, Fort Wayne
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
招募中1/2 期
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
招募中3 期
- Parkview Research Center at Parkview Regional Medical Center ( Site 0002), Fort Wayne
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
招募中2 期
- Fort Wayne Oncology and Hematology, Fort Wayne
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
招募中3 期
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
招募中1 期
- American Oncology Partners, Fort Wayne
其他城市的 慢性淋巴性白血病 試驗
- Boston, MA31 項研究
- Columbus, OH28 項研究
- Durham, NC27 項研究
- Washington, DC22 項研究
- Seattle, WA20 項研究
- Rochester, MN18 項研究
- New York City, NY18 項研究
- Houston, TX17 項研究
- Baldwin Park, CA16 項研究
- Milwaukee, WI15 項研究
- Chicago, IL14 項研究
- Cincinnati, OH14 項研究
Fort Wayne 的其他研究
- 非小細胞肺癌17 項研究
- 卵巢癌8 項研究
- 癌症（所有類型）7 項研究
- 乳癌7 項研究
- 肺癌6 項研究
- 轉移性癌症6 項研究
- 子宮內膜癌5 項研究
- 黑色素瘤4 項研究
- 頭頸部鱗狀細胞癌4 項研究
- 三陰性乳癌4 項研究
- 大腸直腸癌4 項研究
- 多發性骨髓瘤4 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。